Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 179

1.

Cognitive effects of topiramate in migraine patients aged 12 through 17 years.

Pandina GJ, Ness S, Polverejan E, Yuen E, Eerdekens M, Bilder RM, Ford L.

Pediatr Neurol. 2010 Mar;42(3):187-95. doi: 10.1016/j.pediatrneurol.2009.10.001.

PMID:
20159428
2.

Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.

Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ; TOPMAT-MIG-201(TOP-CHROME) Study Group..

Cephalalgia. 2007 Jul;27(7):814-23. Epub 2007 Apr 18. Erratum in: Cephalalgia. 2007 Aug;27(8):962.

PMID:
17441971
3.

Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.

Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, Brandes JL, Bigal M, Saper J, Ascher S, Jordan DM, Greenberg SJ, Hulihan J; Topiramate Chronic Migraine Study Group..

Headache. 2007 Feb;47(2):170-80.

PMID:
17300356
4.

Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial.

Winner P, Pearlman EM, Linder SL, Jordan DM, Fisher AC, Hulihan J; Topiramate Pediatric Migraine Study Investigators..

Headache. 2005 Nov-Dec;45(10):1304-12.

PMID:
16324162
5.

The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials.

Dahlöf C, Loder E, Diamond M, Rupnow M, Papadopoulos G, Mao L.

Health Qual Life Outcomes. 2007 Oct 4;5:56.

6.

Time course of adverse events most commonly associated with topiramate for migraine prevention.

Láinez MJ, Freitag FG, Pfeil J, Ascher S, Olson WH, Schwalen S.

Eur J Neurol. 2007 Aug;14(8):900-6.

PMID:
17662012
7.

The impact of topiramate on health-related quality of life indicators in chronic migraine.

Dodick DW, Silberstein S, Saper J, Freitag FG, Cady RK, Rapoport AM, Mathew NT, Hulihan J, Crivera C, Rupnow MF, Mao L, Finlayson G, Greenberg SJ.

Headache. 2007 Nov-Dec;47(10):1398-408.

PMID:
18052949
8.

Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age.

Lewis D, Winner P, Saper J, Ness S, Polverejan E, Wang S, Kurland CL, Nye J, Yuen E, Eerdekens M, Ford L.

Pediatrics. 2009 Mar;123(3):924-34. doi: 10.1542/peds.2008-0642.

PMID:
19255022
9.

Analysis of safety and tolerability data obtained from over 1,500 patients receiving topiramate for migraine prevention in controlled trials.

Adelman J, Freitag FG, Lainez M, Shi Y, Ascher S, Mao L, Greenberg S, Hulihan J.

Pain Med. 2008 Mar;9(2):175-85. doi: 10.1111/j.1526-4637.2007.00389.x.

PMID:
18298700
10.

Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs.

Dodick DW, Freitag F, Banks J, Saper J, Xiang J, Rupnow M, Biondi D, Greenberg SJ, Hulihan J; CAPSS-277 Investigator Group..

Clin Ther. 2009 Mar;31(3):542-59. doi: 10.1016/j.clinthera.2009.03.020.

PMID:
19393844
11.

Topiramate in migraine prevention: a double-blind, placebo-controlled study.

Storey JR, Calder CS, Hart DE, Potter DL.

Headache. 2001 Nov-Dec;41(10):968-75.

PMID:
11903524
12.

Topiramate for migraine prevention in adolescents: a pooled analysis of efficacy and safety.

Winner P, Gendolla A, Stayer C, Wang S, Yuen E, Battisti WP, Nye JS.

Headache. 2006 Nov-Dec;46(10):1503-10.

PMID:
17115983
13.

Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures.

Silberstein S, Lipton R, Dodick D, Freitag F, Mathew N, Brandes J, Bigal M, Ascher S, Morein J, Wright P, Greenberg S, Hulihan J.

Headache. 2009 Sep;49(8):1153-62. doi: 10.1111/j.1526-4610.2009.01508.x.

PMID:
19719543
14.

The impact of migraine on daily activities: effect of topiramate compared with placebo.

Silberstein SD, Loder E, Forde G, Papadopoulos G, Fairclough D, Greenberg S.

Curr Med Res Opin. 2006 Jun;22(6):1021-9.

PMID:
16846536
15.
16.
17.

Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study.

Lipton RB, Silberstein S, Dodick D, Cady R, Freitag F, Mathew N, Biondi DM, Ascher S, Olson WH, Hulihan J.

Cephalalgia. 2011 Jan;31(1):18-30. doi: 10.1177/0333102410372427. Epub 2010 May 17.

PMID:
20974598
18.

Analysis of pooled data from two pivotal controlled trials on the efficacy of topiramate in the prevention of migraine.

Freitag FG, Forde G, Neto W, Wang DZ, Schmitt J, Wu SC, Hulihan J.

J Am Osteopath Assoc. 2007 Jul;107(7):251-8.

PMID:
17682112
19.

Rizatriptan for treatment of acute migraine in patients taking topiramate for migraine prophylaxis.

Seeburger JL, Cady RK, Winner P, MacGregor A, Valade D, Ge Y, Zhang Y, Hustad CM, Strickler N, Schaefer E, Connor KM, Ho TW.

Headache. 2012 Jan;52(1):57-67. doi: 10.1111/j.1526-4610.2011.02027.x. Epub 2011 Nov 11.

PMID:
22078129
20.

Topiramate: new indication. Migraine prevention: best avoided.

[No authors listed]

Prescrire Int. 2006 Aug;15(84):132-3.

PMID:
16989025

Supplemental Content

Support Center